Summary & Overview
HCPCS C9477: Injection, elotuzumab, 1 mg
HCPCS Level II code C9477 designates a 1 mg unit of elotuzumab administered as an injectable therapy. Elotuzumab is an immunotherapy agent used in oncology care; labeling a per-milligram unit with a specific HCPCS Level II code supports billing for parenteral drug administration in outpatient and infusion settings. Nationally, precise HCPCS coding for high-cost biologics matters for accurate claims processing, price transparency, and payer coverage determinations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what C9477 represents clinically and operationally, plus context on typical sites of service. The publication summarizes benchmarks and policy considerations relevant to HCPCS-level drug coding, outlines common billing practice themes for injectable oncology agents, and highlights areas where payers and providers often align or differ on coverage and reimbursement procedures.
This summary is intended for a national audience of clinicians, coding professionals, and policy analysts seeking a clear description of HCPCS Level II code C9477 and its role in billing for elotuzumab injections.
Billing Code Overview
HCPCS Level II code C9477 represents Injection, elotuzumab, 1 mg. This code describes the administration of the monoclonal antibody elotuzumab in a measured 1 mg unit.
-
Service type: Parenteral drug administration (intravenous or specified injectable route)
-
Typical site of service: Infusion center, outpatient hospital, or physician office where antineoplastic or immunotherapy injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with relapsed or refractory multiple myeloma presents to an outpatient oncology infusion suite for targeted monoclonal antibody therapy. The patient is a 62-year-old receiving elotuzumab administered intravenously as part of combination therapy. The typical workflow includes pre-infusion assessment (vital signs, medication reconciliation, review of prior infusion reactions), premedication (antihistamine, corticosteroid, antipyretic) given orally or IV, IV catheter placement or use of an implanted port, pharmacy preparation and verification of elotuzumab (dosing in mg based on body surface area or weight per prescribing information), and infusion over the recommended infusion time with periodic vital signs and monitoring for infusion-related reactions. Post-infusion observation for delayed reactions and discharge instructions are provided. The service described by C9477 (Injection, elotuzumab, 1 mg) is reported per milligram of drug administered for billing and inventory reconciliation. Typical site of service is an outpatient hospital infusion center, physician office infusion suite, or ambulatory infusion center. Expected patient scenario includes ongoing monitoring of hematologic status and concurrent administration of partner agents such as lenalidomide or pomalidomide per the treating hematologist/oncologist’s regimen.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|